New hope for aggressive leukemia: gentler chemo before transplant shows promise
NCT ID NCT07259161
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 19 times
Summary
This study tests a milder chemotherapy combination (thiotepa and melphalan) given before a stem cell transplant for people with blast phase chronic myeloid leukemia, an advanced and hard-to-treat form of the disease. The goal is to improve survival while reducing serious side effects. About 40 participants will be enrolled to see how well this approach works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HSCT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.